AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma

approvedC-CAR039Prizlon-celPositive

AI Analysis

Summary

AbelZeta announced FDA clearance of an IND application for C-CAR039 (Prizlon-cel) in large B-cell lymphoma and regained global rights to the candidate. The company is advancing this cell-based therapeutic toward clinical development.

Outcome Details

FDA clearance of IND application

Importance:7/10

Sentiment:

0.85

cell-based therapeuticsCAR-TlymphomaIND clearanceglobal rights

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on August 17, 2026 12:00 AM

Read Original